A password will be e-mailed to you.

Anxiety May Be An Early Indicator of Alzheimer’s

Summary: Researchers have discovered a link between elevated levels of amyloid beta and worsening anxiety symptoms. The research supports the hypothesis that some psychiatric symptoms could indicate the early stages of Alzheimer’s disease.

Source: Brigham and Women’s Hospital.

A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of Alzheimer’s disease in older adults.

Alzheimer’s disease is a neurodegenerative condition that causes the decline of cognitive function and the inability to carry out daily life activities. Past studies have suggested depression and other neuropsychiatric symptoms may be predictors of AD’s progression during its “preclinical” phase, during which time brain deposits of fibrillar amyloid and pathological tau accumulate in a patient’s brain. This phase can occur more than a decade before a patient’s onset of mild cognitive impairment. Investigators at Brigham and Women’s Hospital examined the association of brain amyloid beta and longitudinal measures of depression and depressive symptoms in cognitively normal, older adults. Their findings, published today by The American Journal of Psychiatry, suggest that higher levels of amyloid beta may be associated with increasing symptoms of anxiety in these individuals. These results support the theory that neuropsychiatric symptoms could be an early indicator of AD.

“Rather than just looking at depression as a total score, we looked at specific symptoms such as anxiety. When compared to other symptoms of depression such as sadness or loss of interest, anxiety symptoms increased over time in those with higher amyloid beta levels in the brain,” said first author Nancy Donovan, MD, a geriatric psychiatrist at Brigham and Women’s Hospital. “This suggests that anxiety symptoms could be a manifestation of Alzheimer’s disease prior to the onset of cognitive impairment. If further research substantiates anxiety as an early indicator, it would be important for not only identifying people early on with the disease, but also, treating it and potentially slowing or preventing the disease process early on.” As anxiety is common in older people, rising anxiety symptoms may prove to be most useful as a risk marker in older adults with other genetic, biological or clinical indicators of high AD risk.

an old man

Alzheimer’s disease is a neurodegenerative condition that causes the decline of cognitive function and the inability to carry out daily life activities. NeuroscienceNews.com image is in the public domain.

Researchers derived data from the Harvard Aging Brain Study, an observational study of older adult volunteers aimed at defining neurobiological and clinical changes in early Alzheimer’s disease. The participants included 270 community dwelling, cognitively normal men and women, between 62 and 90 years old, with no active psychiatric disorders. Individuals also underwent baseline imaging scans commonly used in studies of Alzheimer’s disease, and annual assessments with the 30-item Geriatric Depression Scale (GDS), an assessment used to detect depression in older adults.

The team calculated total GDS scores as well as scores for three clusters symptoms of depression: apathy-anhedonia, dysphoria, and anxiety. These scores were looked at over a span of five years.

From their research, the team found that higher brain amyloid beta burden was associated with increasing anxiety symptoms over time in cognitively normal older adults. The results suggest that worsening anxious-depressive symptoms may be an early predictor of elevated amyloid beta levels – and, in turn AD — and provide support for the hypothesis that emerging neuropsychiatric symptoms represent an early manifestation of preclinical Alzheimer’s disease.

Donovan notes further longitudinal follow-up is needed to determine whether these escalating depressive symptoms give rise to clinical depression and dementia stages of Alzheimer’s disease over time.

About this neuroscience research article

Funding: The study was supported by the National Institute on Aging (grants R03 AG045080, R01 AG027435, K24 AG035007), the Harvard Medical School Department of Psychiatry Dupont-Warren Fellowship and Livingston Award, the Rogers Family Foundation, the Massachusetts Alzheimer’s Disease Research Center (grant P50 AG005134), and the Harvard Aging Brain Study (grants P01 AGO36694, R01 AG037497). Dr. Donovan received salary support from Eisai and Eli Lilly; her spouse is employed by Alkermes. Dr. Marshall has received salary support from Eisai and Eli Lilly and has served as a consultant for Halloran and GliaCure. Dr. Hanseeuw has received grants from the Belgian National Science Foundation (grant SPD28094292) and the Belgian Foundation for Alzheimer Research (grant P16008) and has served on an advisory board as a paid consultant for GE Healthcare. Dr. Rentz has served as a consultant for Eli Lilly, Janssen Alzheimer Immunotherapy, Biogen Idek, and Lundbeck Pharmaceuticals, and she has served on the scientific advisory board for Neurotrack. Dr. Johnson has served as a consultant for AbbVie, AZtherapies, Biogen, Bristol-Myers Squibb, GE Healthcare, Genentech, Genzyme, Isis Pharmaceuticals, Janssen Alzheimer’s Immunotherapy, Lundbeck, Merck, Novartis, Piramal, Roche, and Siemens Medical Solutions; he is a site principal investigator or co-investigator for Biogen, Eisai, Eli Lilly/Avid, Janssen Alzheimer Immunotherapy, Merck, and Navidea clinical trials; and he has spoken at symposia sponsored by GE Healthcare, Janssen Alzheimer’s Immunotherapy, Lundbeck, and Pfizer. Dr. Sperling has served as a consultant for AbbVie, Biogen, Bracket, GE, Genentech, Lundbeck, Merck, Otsuka, Pfizer, Roche, and Sanofi; she has served as a co-investigator for Avid, Eli Lilly, and Janssen Alzheimer Immunotherapy clinical trials; she has spoken at symposia sponsored by Biogen, Eli Lilly, and Janssen Alzheimer Immunotherapy; and her spouse has received payments from Lundbeck, Novartis, Piramal Healthcare, and Siemens. The other authors report no financial relationships with commercial interests.

Source: Johanna Younghans – Brigham and Women’s Hospital
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is in the public domain.
Original Research: Abstract for “Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults” by Nancy J. Donovan, M.D., Joseph J. Locascio, Ph.D., Gad A. Marshall, M.D., Jennifer Gatchel, M.D., Ph.D., Bernard J. Hanseeuw, M.D., Ph.D., Dorene M. Rentz, Psy.D., Keith A. Johnson, M.D., Reisa A. Sperling, M.D., for the Harvard Aging Brain Study in American Journal of Psychiatry. Published online January 12 2018 doi:10.1176/appi.ajp.2017.17040442

Cite This NeuroscienceNews.com Article
Brigham and Women’s Hospital “Anxiety May Be An Early Indicator of Alzheimer’s.” NeuroscienceNews. NeuroscienceNews, 12 January 2018.
<http://neurosciencenews.com/alzheimers-anxiety-8302/>.
Brigham and Women’s Hospital (2018, January 12). Anxiety May Be An Early Indicator of Alzheimer’s. NeuroscienceNews. Retrieved January 12, 2018 from http://neurosciencenews.com/alzheimers-anxiety-8302/
Brigham and Women’s Hospital “Anxiety May Be An Early Indicator of Alzheimer’s.” http://neurosciencenews.com/alzheimers-anxiety-8302/ (accessed January 12, 2018).

Abstract

Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults

Objective:
To understand the role of depressive symptoms in preclinical Alzheimer’s disease, it is essential to define their temporal relationship to Alzheimer’s proteinopathies in cognitively normal older adults. The study objective was to examine associations of brain amyloid beta and longitudinal measures of depression and depressive symptom clusters in a cognitively normal sample of older adults.

Method:
A total of 270 community-dwelling, cognitively normal elderly individuals underwent baseline Pittsburgh compound B (PiB) positron emission tomography (PET) measures of cortical aggregate amyloid beta and annual assessments with the 30-item Geriatric Depression Scale (GDS). The authors evaluated continuous PiB binding as a predictor of GDS score or GDS cluster, calculated as total scores and mean scores for three GDS item clusters (apathy-anhedonia, dysphoria, and anxiety-concentration), across time (1–5 years; mean=3.8 years) in separate mixed-effects models with backward elimination. Initial predictors included PiB binding, age, sex, Hollingshead score, American National Adult Reading Test (AMNART) score, apolipoprotein E ε4 status, depression history, and their interactions with time.

Results:
Higher PiB binding predicted accelerated rates of increase in GDS score over time, adjusting for depression history. Higher PiB binding also predicted steeper rates of increase for anxiety-concentration scores, adjusting for depression history and the AMNART score-by-time interaction. In a post hoc model estimating anxiety scores without concentration disturbance items, the PiB binding-by-time interaction remained significant.

Conclusions:
Higher amyloid beta burden was associated with increasing anxious-depressive symptoms over time in cognitively normal older individuals. Prior depression history was related to higher but not worsening symptom ratings. These results suggest a direct or indirect association of elevated amyloid beta levels with worsening anxious-depressive symptoms and support the hypothesis that emerging neuropsychiatric symptoms represent an early manifestation of preclinical Alzheimer’s disease.

“Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults” by Nancy J. Donovan, M.D., Joseph J. Locascio, Ph.D., Gad A. Marshall, M.D., Jennifer Gatchel, M.D., Ph.D., Bernard J. Hanseeuw, M.D., Ph.D., Dorene M. Rentz, Psy.D., Keith A. Johnson, M.D., Reisa A. Sperling, M.D., for the Harvard Aging Brain Study in American Journal of Psychiatry. Published online January 12 2018 doi:10.1176/appi.ajp.2017.17040442

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.
No more articles